These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 10861749)
1. The Dunning model. Tennant TR; Kim H; Sokoloff M; Rinker-Schaeffer CW Prostate; 2000 Jun; 43(4):295-302. PubMed ID: 10861749 [No Abstract] [Full Text] [Related]
2. Progression model of prostate cancer. Almeida TA; Papadopoulos N Methods Mol Biol; 2003; 222():211-22. PubMed ID: 12710689 [No Abstract] [Full Text] [Related]
3. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Bussemakers MJ; van Moorselaar RJ; Giroldi LA; Ichikawa T; Isaacs JT; Takeichi M; Debruyne FM; Schalken JA Cancer Res; 1992 May; 52(10):2916-22. PubMed ID: 1581909 [TBL] [Abstract][Full Text] [Related]
4. Prediction of metastatic potential by cancer cell motility in the Dunning R-3327 prostatic adenocarcinoma in vivo model. Doyle GM; Sharief Y; Mohler JL J Urol; 1992 Feb; 147(2):514-8. PubMed ID: 1732634 [TBL] [Abstract][Full Text] [Related]
5. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Vieweg J; Boczkowski D; Roberson KM; Edwards DW; Philip M; Philip R; Rudoll T; Smith C; Robertson C; Gilboa E Cancer Res; 1995 Jun; 55(11):2366-72. PubMed ID: 7757988 [TBL] [Abstract][Full Text] [Related]
11. Dunning rat prostate tumors and cultured cell lines fail to express human prostate carcinoma-associated antigens. Newhall KR; Isaacs JT; Wright GL Prostate; 1990; 17(4):317-25. PubMed ID: 1701250 [TBL] [Abstract][Full Text] [Related]
12. Antitumoral local effect and metastatic risk of focused extracorporeal pyrotherapy on Dunning R-3327 tumors. Bataille N; Vallancien G; Chopin D Eur Urol; 1996; 29(1):72-7. PubMed ID: 8821695 [TBL] [Abstract][Full Text] [Related]
13. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. Kasper S; Smith JA J Urol; 2004 Jul; 172(1):12-9. PubMed ID: 15201729 [TBL] [Abstract][Full Text] [Related]
14. Immunologic aspects of the prostate. Lubaroff DM; Reynolds CW; Canfield L; McElligott D; Feldbush T Prostate; 1981; 2(3):233-48. PubMed ID: 6170966 [TBL] [Abstract][Full Text] [Related]
15. Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Yedavelli SP; Guo L; Daou ME; Srivastava PK; Mittelman A; Tiwari RK Int J Mol Med; 1999 Sep; 4(3):243-8. PubMed ID: 10425272 [TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of MAT LyLu: a Dunning rat prostate adenocarcinoma tumor subline. Wenger AS; Mickey DD; Hall M; Silverman LM; Mickey GH; Fried FA J Urol; 1984 Jun; 131(6):1232-6. PubMed ID: 6539387 [TBL] [Abstract][Full Text] [Related]
17. Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Isaacs JT; Heston WD; Weissman RM; Coffey DS Cancer Res; 1978 Nov; 38(11 Pt 2):4353-9. PubMed ID: 698976 [TBL] [Abstract][Full Text] [Related]
18. p62 - a new metabolic tumour suppressor. Leong I Nat Rev Endocrinol; 2018 Jun; 14(6):324. PubMed ID: 29692410 [No Abstract] [Full Text] [Related]
19. Epidermal growth factor receptor content in rat prostatic adenocarcinoma: effects of endocrine treatment. Damber JE; Bergh A; Assarsson B; Gåfvels M Urol Res; 1995; 23(2):119-25. PubMed ID: 7676534 [TBL] [Abstract][Full Text] [Related]
20. Flow cytometric assay of pinocytosis: correlation with membrane ruffling and metastatic potential in the Dunning R-3327 rat prostatic adenocarcinoma model. Mohler JL; Sharief Y Cytometry; 1993 Oct; 14(7):826-31. PubMed ID: 8243212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]